SVB Leerink

Selected news for the capital firm - SVB Leerink, collected since 4/2019. Recent stories appear in slatersentinel.com and Daily Political. This capital firm shares healthcare news with Medical Research, Oncology, HealthEquity, Pfizer, Allscripts and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
7/6/2021 First Mercantile Trust Co. Cuts Position in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) zolmax.com ... worth about $163,000. Finally, Truist Financial Corp purchased a new stake in shares of Allscripts Healthcare Solutions during the fourth quarter worth about $205,000. A number of research firms recently issued reports on MDRX. SVB Leerink increased their price target on shares of Allscripts Healthcare Solutions from $16.00 to $17.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 26th. Deutsche Bank Aktiengesellschaft ...
7/6/2021 SVB Leerink Reiterates “Buy” Rating for BioMarin Pharmaceutical (NASDAQ:BMRN) - The Cerbat Gem thecerbatgem.com SVB Leerink reissued their buy rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research report sent to investors on Friday, Price Targets.com reports.BMRN has been the topic of several other reports. Credit Suisse Group assumed coverage on shares of BioMarin Pharmaceutical in a research report on Monday, April 26th. They issued an outperform rating and a $102.00 price target on the stock. Wedbush reiterated a buy rating ...
7/6/2021 SVB Leerink Reiterates “Buy” Rating for BioMarin Pharmaceutical (NASDAQ:BMRN) - Watch List News watchlistnews.com SVB Leerink restated their buy rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research report released on Friday morning, PriceTargets.com reports.A number of other equities research analysts have also commented on the stock. Credit Suisse Group started coverage on shares of BioMarin Pharmaceutical in a report on Monday, April 26th. They set an outperform rating and a $102.00 price objective on the stock. Morgan Stanley decreased their ...
7/6/2021 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives Consensus Rating of “Buy” from Analysts slatersentinel.com ... analysts recently commented on the company. Citigroup initiated coverage on Arena Pharmaceuticals in a research report on Tuesday, April 27th. They issued a “buy” rating and a $104.00 target price on the stock. SVB Leerink boosted their price objective on Arena Pharmaceuticals from $90.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, May 7th. Zacks Investment Research cut Arena Pharmaceuticals from ...
6/25/2021 Allscripts Healthcare Solutions (NASDAQ:MDRX) Hits New 1-Year High at $18.30 - Ticker Report Ticker Report ... April 30th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Allscripts Healthcare Solutions from $15.00 to $17.00 and gave the company a “hold” rating in a report on Thursday, May 20th. SVB Leerink upped their price target on Allscripts Healthcare Solutions from $16.00 to $17.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 26th. Argus reiterated a “hold” ...
6/21/2021 UBS Group Reiterates Buy Rating for AstraZeneca (NASDAQ:AZN) rivertonroll.com ... upgraded AstraZeneca from a hold rating to a buy rating in a report on Tuesday, March 16th. Berenberg Bank reiterated a buy rating on shares of AstraZeneca in a report on Tuesday, March 9th. SVB Leerink increased their price target on AstraZeneca from $63.00 to $64.00 and gave the company an outperform rating in a report on Friday, June 4th. Argus reiterated a hold rating on shares of AstraZeneca in ...
6/21/2021 UBS Group Reiterates Buy Rating for AstraZeneca (NASDAQ:AZN) - Mayfield Recorder Mayfield Recorder UBS Group reissued their buy rating on shares of AstraZeneca (NASDAQ:AZN) in a research note issued to investors on Thursday morning, The Fly reports.Several other brokerages have also recently commented on AZN. SVB Leerink raised their price objective on shares of AstraZeneca from $63.00 to $64.00 and gave the company an outperform rating in a research note on Friday, June 4th. Societe Generale reiterated a buy rating on ...
6/16/2021 Ascendis Pharma A/S (NASDAQ:ASND) Forecasted to Earn Q3 2021 Earnings of ($2.96) Per Share - Dakota Financial News Dakota Financial News Ascendis Pharma A/S (NASDAQ:ASND) – SVB Leerink cut their Q3 2021 earnings estimates for shares of Ascendis Pharma A/S in a research report issued on Sunday, June 13th. SVB Leerink analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($2.96) for the quarter, down from their previous forecast of ($2.82). SVB Leerink currently has a “Outperform” rating and a $181.00 ...
6/13/2021 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Rating of “Buy” from Analysts - Transcript Daily transcriptdaily.com ... Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating and set a $181.00 price target on the stock in a research report on Wednesday, March 17th. SVB Leerink reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Sunday, May 9th. Stifel Nicolaus lifted their price target on shares of Jazz Pharmaceuticals from $195.00 to $202.00 and ...
6/11/2021 Raymond James Reiterates “Buy” Rating for Intellia Therapeutics (NASDAQ:NTLA) - Ticker Report Ticker Report ... They issued an “outperform” rating and a $80.00 target price for the company. Truist upped their target price on Intellia Therapeutics from $40.00 to $80.00 in a research report on Friday, February 26th. SVB Leerink reissued a “buy” rating on shares of Intellia Therapeutics in a research report on Sunday, March 21st. Royal Bank of Canada initiated coverage on Intellia Therapeutics in a research report on Monday, May ...
6/11/2021 Raymond James Reiterates “Buy” Rating for Intellia Therapeutics (NASDAQ:NTLA) - Watch List News watchlistnews.com ... on the company. Royal Bank of Canada began coverage on Intellia Therapeutics in a research note on Monday, May 3rd. They issued an “outperform” rating and a $110.00 price target for the company. SVB Leerink reiterated a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, March 21st. Roth Capital upgraded Intellia Therapeutics from a “neutral” rating to a “buy” rating and ...
6/11/2021 LifeMD (NASDAQ:LFMD) Earns Buy Rating from BTIG Research | Daily Political Daily Political ... subject of a number of other reports. Robert W. Baird raised their price objective on shares of Phreesia from $60.00 to $62.00 and gave the stock an outperform rating in a report on Monday. SVB Leerink reaffirmed a buy rating on shares of Phreesia in a report on Sunday, June 6th. Piper Sandler raised their price objective on shares of Phreesia from $58.00 to $63.50 and gave the stock an ...
6/11/2021 Berenberg Bank Begins Coverage on Phreesia (NYSE:PHR) zolmax.com ... rating in a research report on Monday. Robert W. Baird lifted their price objective on shares of Phreesia from $60.00 to $62.00 and gave the stock an outperform rating in a report on Monday. SVB Leerink reaffirmed a buy rating on shares of Phreesia in a report on Sunday, June 6th. JPMorgan Chase & Co. assumed coverage on shares of Phreesia in a report on Thursday, April 29th. They issued an ...
6/11/2021 Tomra Systems ASA (OTCMKTS:TMRAY) Short Interest Down 85.0% in May | Daily Political Daily Political ... an outperform rating in a report on Monday. Berenberg Bank initiated coverage on shares of Phreesia in a report on Tuesday. They set a buy rating and a $70.00 target price on the stock. SVB Leerink restated a buy rating on shares of Phreesia in a report on Sunday, June 6th. KeyCorp reduced their target price on shares of Phreesia from $80.00 to $70.00 and set an overweight rating on ...
6/11/2021 Phreesia (NYSE:PHR) Updates FY 2022 Earnings Guidance - Ticker Report Ticker Report ... an outperform rating in a report on Monday. Piper Sandler upped their price objective on shares of Phreesia from $58.00 to $63.50 and gave the company an overweight rating in a report on Monday. SVB Leerink reiterated a buy rating on shares of Phreesia in a report on Sunday, June 6th. Berenberg Bank started coverage on shares of Phreesia in a report on Tuesday. They issued a buy rating and ...
6/10/2021 Intellia Therapeutics (NASDAQ:NTLA) Earns “Buy” Rating from Raymond James thelincolnianonline.com ... from $75.00 to $80.00 in a research report on Friday, May 7th. Zacks Investment Research upgraded Intellia Therapeutics from a sell rating to a hold rating in a research report on Wednesday, March 3rd. SVB Leerink restated a buy rating on shares of Intellia Therapeutics in a research report on Sunday, March 21st. Royal Bank of Canada began coverage on Intellia Therapeutics in a research report on Monday, May 3rd ...
6/10/2021 Q2 2021 Earnings Forecast for BeiGene, Ltd. Issued By SVB Leerink (NASDAQ:BGNE) rivertonroll.com Q2 2021 Earnings Forecast for BeiGene, Ltd. Issued By SVB Leerink (NASDAQ:BGNE) Posted by Lars Charter on Jun 10th, 2021 Share on StocktwitsBeiGene, Ltd. (NASDAQ:BGNE) – SVB Leerink cut their Q2 2021 earnings estimates for shares of BeiGene in a report released on Monday, June 7th. SVB Leerink analyst A. Berens now expects that the company will earn ($4.64) per share for the quarter, down from their ...
6/10/2021 Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.5% American Banking News ... shares traded hands during mid-day trading, a decline of 99% from the average session volume of 447,151 shares. The stock had previously closed at $94.38.Several research firms recently issued reports on RARE. SVB Leerink began coverage on shares of Ultragenyx Pharmaceutical in a report on Sunday, May 9th. They issued a “buy” rating and a $178.00 target price on the stock. Zacks Investment Research lowered shares of ...
6/10/2021 Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.5% - Watch List News watchlistnews.com ... shares traded hands during mid-day trading, a decline of 99% from the average session volume of 447,151 shares. The stock had previously closed at $94.38.Several research firms recently issued reports on RARE. SVB Leerink began coverage on shares of Ultragenyx Pharmaceutical in a report on Sunday, May 9th. They issued a “buy” rating and a $178.00 target price on the stock. Zacks Investment Research lowered shares of ...
6/9/2021 Alexion Pharmaceuticals (NASDAQ:ALXN) Hits New 52-Week High at $179.37 baseballnewssource.com ... Oppenheimer upgraded shares of Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $205.00 price objective on the stock in a research note on Wednesday, May 5th. SVB Leerink upped their price objective on Alexion Pharmaceuticals from $156.00 to $173.00 and gave the company a “market perform” rating in a report on Monday, May 3rd. Finally, Credit Suisse Group initiated coverage on ...